Archive: 09/10/2019

Long-term dupilumab benefits adolescents with eczema

Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can ...

page 10 from 11